ID   TOR1_YEAST              Reviewed;        2470 AA.
AC   P35169; D6VWN7;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 3.
DT   18-JUN-2025, entry version 226.
DE   RecName: Full=Serine/threonine-protein kinase TOR1;
DE            EC=2.7.11.1 {ECO:0000269|PubMed:10436010, ECO:0000305|PubMed:34535752};
DE   AltName: Full=Dominant rapamycin resistance protein 1;
DE   AltName: Full=Phosphatidylinositol kinase homolog TOR1;
DE   AltName: Full=Target of rapamycin kinase 1;
GN   Name=TOR1; Synonyms=DRR1; OrderedLocusNames=YJR066W; ORFNames=J1803;
OS   Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast).
OC   Eukaryota; Fungi; Dikarya; Ascomycota; Saccharomycotina; Saccharomycetes;
OC   Saccharomycetales; Saccharomycetaceae; Saccharomyces.
OX   NCBI_TaxID=559292;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND MUTAGENESIS OF SER-1972.
RC   STRAIN=RC11-8D;
RX   PubMed=8413204; DOI=10.1128/mcb.13.10.6012-6023.1993;
RA   Cafferkey R., Young P.R., McLaughlin M.M., Bergsma D.J., Koltin Y.,
RA   Sathe G.M., Faucette L., Eng W.-K., Johnson R.K., Livi G.P.;
RT   "Dominant missense mutations in a novel yeast protein related to mammalian
RT   phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity.";
RL   Mol. Cell. Biol. 13:6012-6023(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=JK9-3D;
RX   PubMed=8186460; DOI=10.1091/mbc.5.1.105;
RA   Helliwell S.B., Wagner P., Kunz J., Deuter-Reinhard M., Henriquez R.,
RA   Hall M.N.;
RT   "TOR1 and TOR2 are structurally and functionally similar but not identical
RT   phosphatidylinositol kinase homologues in yeast.";
RL   Mol. Biol. Cell 5:105-118(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=ATCC 204508 / S288c;
RX   PubMed=8840504;
RX   DOI=10.1002/(sici)1097-0061(199607)12:9%3c869::aid-yea964%3e3.0.co;2-1;
RA   Huang M.-E., Manus V., Chuat J.-C., Galibert F.;
RT   "Analysis of a 62 kb DNA sequence of chromosome X reveals 36 open reading
RT   frames and a gene cluster with a counterpart on chromosome XI.";
RL   Yeast 12:869-875(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 204508 / S288c;
RX   PubMed=8641269; DOI=10.1002/j.1460-2075.1996.tb00557.x;
RA   Galibert F., Alexandraki D., Baur A., Boles E., Chalwatzis N., Chuat J.-C.,
RA   Coster F., Cziepluch C., de Haan M., Domdey H., Durand P., Entian K.-D.,
RA   Gatius M., Goffeau A., Grivell L.A., Hennemann A., Herbert C.J.,
RA   Heumann K., Hilger F., Hollenberg C.P., Huang M.-E., Jacq C.,
RA   Jauniaux J.-C., Katsoulou C., Kirchrath L., Kleine K., Kordes E.,
RA   Koetter P., Liebl S., Louis E.J., Manus V., Mewes H.-W., Miosga T.,
RA   Obermaier B., Perea J., Pohl T.M., Portetelle D., Pujol A., Purnelle B.,
RA   Ramezani Rad M., Rasmussen S.W., Rose M., Rossau R.,
RA   Schaaff-Gerstenschlaeger I., Smits P.H.M., Scarcez T., Soriano N.,
RA   To Van D., Tzermia M., Van Broekhoven A., Vandenbol M., Wedler H.,
RA   von Wettstein D., Wambutt R., Zagulski M., Zollner A., Karpfinger-Hartl L.;
RT   "Complete nucleotide sequence of Saccharomyces cerevisiae chromosome X.";
RL   EMBO J. 15:2031-2049(1996).
RN   [5]
RP   GENOME REANNOTATION.
RC   STRAIN=ATCC 204508 / S288c;
RX   PubMed=24374639; DOI=10.1534/g3.113.008995;
RA   Engel S.R., Dietrich F.S., Fisk D.G., Binkley G., Balakrishnan R.,
RA   Costanzo M.C., Dwight S.S., Hitz B.C., Karra K., Nash R.S., Weng S.,
RA   Wong E.D., Lloyd P., Skrzypek M.S., Miyasato S.R., Simison M., Cherry J.M.;
RT   "The reference genome sequence of Saccharomyces cerevisiae: Then and now.";
RL   G3 (Bethesda) 4:389-398(2014).
RN   [6]
RP   FUNCTION, MUTAGENESIS OF SER-1972; ARG-2276 AND ASP-2294, AND INTERACTION
RP   WITH FPR1.
RX   PubMed=7606777; DOI=10.1016/0092-8674(95)90058-6;
RA   Zheng X.-F., Florentino D., Chen J., Crabtree G.R., Schreiber S.L.;
RT   "TOR kinase domains are required for two distinct functions, only one of
RT   which is inhibited by rapamycin.";
RL   Cell 82:121-130(1995).
RN   [7]
RP   FUNCTION.
RX   PubMed=8741837; DOI=10.1091/mbc.7.1.25;
RA   Barbet N.C., Schneider U., Helliwell S.B., Stansfield I., Tuite M.F.,
RA   Hall M.N.;
RT   "TOR controls translation initiation and early G1 progression in yeast.";
RL   Mol. Biol. Cell 7:25-42(1996).
RN   [8]
RP   FUNCTION.
RX   PubMed=9843498; DOI=10.1093/emboj/17.23.6924;
RA   Schmidt A., Beck T., Koller A., Kunz J., Hall M.N.;
RT   "The TOR nutrient signalling pathway phosphorylates NPR1 and inhibits
RT   turnover of the tryptophan permease.";
RL   EMBO J. 17:6924-6931(1998).
RN   [9]
RP   FUNCTION.
RX   PubMed=9539725; DOI=10.1073/pnas.95.8.4264;
RA   Berset C., Trachsel H., Altmann M.;
RT   "The TOR (target of rapamycin) signal transduction pathway regulates the
RT   stability of translation initiation factor eIF4G in the yeast Saccharomyces
RT   cerevisiae.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:4264-4269(1998).
RN   [10]
RP   FUNCTION.
RX   PubMed=10329624; DOI=10.1093/emboj/18.10.2782;
RA   Jiang Y., Broach J.R.;
RT   "Tor proteins and protein phosphatase 2A reciprocally regulate Tap42 in
RT   controlling cell growth in yeast.";
RL   EMBO J. 18:2782-2792(1999).
RN   [11]
RP   FUNCTION.
RX   PubMed=10198052; DOI=10.1091/mbc.10.4.987;
RA   Powers T., Walter P.;
RT   "Regulation of ribosome biogenesis by the rapamycin-sensitive TOR-signaling
RT   pathway in Saccharomyces cerevisiae.";
RL   Mol. Biol. Cell 10:987-1000(1999).
RN   [12]
RP   CATALYTIC ACTIVITY, AND MUTAGENESIS OF ASP-2275.
RX   PubMed=10436010; DOI=10.1091/mbc.10.8.2531;
RA   Alarcon C.M., Heitman J., Cardenas M.E.;
RT   "Protein kinase activity and identification of a toxic effector domain of
RT   the target of rapamycin TOR proteins in yeast.";
RL   Mol. Biol. Cell 10:2531-2546(1999).
RN   [13]
RP   FUNCTION.
RX   PubMed=10604478; DOI=10.1038/45287;
RA   Beck T., Hall M.N.;
RT   "The TOR signalling pathway controls nuclear localization of nutrient-
RT   regulated transcription factors.";
RL   Nature 402:689-692(1999).
RN   [14]
RP   SUBCELLULAR LOCATION.
RX   PubMed=10973982; DOI=10.1074/jbc.m007296200;
RA   Kunz J., Schneider U., Howald I., Schmidt A., Hall M.N.;
RT   "HEAT repeats mediate plasma membrane localization of Tor2p in yeast.";
RL   J. Biol. Chem. 275:37011-37020(2000).
RN   [15]
RP   FUNCTION IN AUTOPHAGY.
RX   PubMed=10995454; DOI=10.1083/jcb.150.6.1507;
RA   Kamada Y., Funakoshi T., Shintani T., Nagano K., Ohsumi M., Ohsumi Y.;
RT   "Tor-mediated induction of autophagy via an Apg1 protein kinase complex.";
RL   J. Cell Biol. 150:1507-1513(2000).
RN   [16]
RP   FUNCTION.
RX   PubMed=11741537; DOI=10.1016/s1097-2765(01)00386-0;
RA   Jacinto E., Guo B., Arndt K.T., Schmelzle T., Hall M.N.;
RT   "TIP41 interacts with TAP42 and negatively regulates the TOR signaling
RT   pathway.";
RL   Mol. Cell 8:1017-1026(2001).
RN   [17]
RP   SUBUNIT.
RX   PubMed=12408816; DOI=10.1016/s1097-2765(02)00636-6;
RA   Loewith R., Jacinto E., Wullschleger S., Lorberg A., Crespo J.L.,
RA   Bonenfant D., Oppliger W., Jenoe P., Hall M.N.;
RT   "Two TOR complexes, only one of which is rapamycin sensitive, have distinct
RT   roles in cell growth control.";
RL   Mol. Cell 10:457-468(2002).
RN   [18]
RP   SUBCELLULAR LOCATION, SUBUNIT, AND INTERACTION WITH KOG1 AND LST8.
RX   PubMed=12631735; DOI=10.1091/mbc.e02-09-0609;
RA   Wedaman K.P., Reinke A., Anderson S., Yates J.R. III, McCaffery J.M.,
RA   Powers T.;
RT   "Tor kinases are in distinct membrane-associated protein complexes in
RT   Saccharomyces cerevisiae.";
RL   Mol. Biol. Cell 14:1204-1220(2003).
RN   [19]
RP   LEVEL OF PROTEIN EXPRESSION [LARGE SCALE ANALYSIS].
RX   PubMed=14562106; DOI=10.1038/nature02046;
RA   Ghaemmaghami S., Huh W.-K., Bower K., Howson R.W., Belle A., Dephoure N.,
RA   O'Shea E.K., Weissman J.S.;
RT   "Global analysis of protein expression in yeast.";
RL   Nature 425:737-741(2003).
RN   [20]
RP   FUNCTION.
RX   PubMed=15620355; DOI=10.1016/j.cell.2004.11.047;
RA   Martin D.E., Soulard A., Hall M.N.;
RT   "TOR regulates ribosomal protein gene expression via PKA and the forkhead
RT   transcription factor FHL1.";
RL   Cell 119:969-979(2004).
RN   [21]
RP   FUNCTION.
RX   PubMed=17560372; DOI=10.1016/j.molcel.2007.04.020;
RA   Urban J., Soulard A., Huber A., Lippman S., Mukhopadhyay D., Deloche O.,
RA   Wanke V., Anrather D., Ammerer G., Riezman H., Broach J.R., De Virgilio C.,
RA   Hall M.N., Loewith R.;
RT   "Sch9 is a major target of TORC1 in Saccharomyces cerevisiae.";
RL   Mol. Cell 26:663-674(2007).
RN   [22]
RP   FUNCTION.
RX   PubMed=25767889; DOI=10.1371/journal.pone.0120250;
RA   Gonzalez A., Shimobayashi M., Eisenberg T., Merle D.A., Pendl T.,
RA   Hall M.N., Moustafa T.;
RT   "TORC1 promotes phosphorylation of ribosomal protein S6 via the AGC kinase
RT   Ypk3 in Saccharomyces cerevisiae.";
RL   PLoS ONE 10:E0120250-E0120250(2015).
RN   [23] {ECO:0000305}
RP   ACTIVITY REGULATION, AND SUBCELLULAR LOCATION.
RC   STRAIN=ATCC 200060 / W303 {ECO:0000303|PubMed:28993463};
RX   PubMed=28993463; DOI=10.1242/jcs.207910;
RA   Varlakhanova N.V., Mihalevic M.J., Bernstein K.A., Ford M.G.J.;
RT   "Pib2 and the EGO complex are both required for activation of TORC1.";
RL   J. Cell Sci. 130:3878-3890(2017).
RN   [24]
RP   ACTIVITY REGULATION, INTERACTION WITH PIB2, AND SUBCELLULAR LOCATION.
RX   PubMed=28483912; DOI=10.1128/mcb.00075-17;
RA   Tanigawa M., Maeda T.;
RT   "An In vitro TORC1 kinase assay that recapitulates the Gtr-independent
RT   glutamine-responsive TORC1 activation mechanism on yeast vacuoles.";
RL   Mol. Cell. Biol. 37:e00075-e00075(2017).
RN   [25]
RP   ACTIVITY REGULATION, INTERACTION WITH PIB2, SUBCELLULAR LOCATION, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=29698392; DOI=10.1371/journal.pgen.1007334;
RA   Ukai H., Araki Y., Kira S., Oikawa Y., May A.I., Noda T.;
RT   "Gtr/Ego-independent TORC1 activation is achieved through a glutamine-
RT   sensitive interaction with Pib2 on the vacuolar membrane.";
RL   PLoS Genet. 14:e1007334-e1007334(2018).
RN   [26]
RP   SUBCELLULAR LOCATION, DISRUPTION PHENOTYPE, AND MUTAGENESIS OF TRP-2176.
RX   PubMed=32801125; DOI=10.1242/jcs.245555;
RA   Uemura S., Mochizuki T., Amemiya K., Kurosaka G., Yazawa M., Nakamoto K.,
RA   Ishikawa Y., Izawa S., Abe F.;
RT   "Amino acid homeostatic control by TORC1 in Saccharomyces cerevisiae under
RT   high hydrostatic pressure.";
RL   J. Cell Sci. 133:jcs245555-jcs245555(2020).
RN   [27]
RP   ACTIVITY REGULATION, CATALYTIC ACTIVITY, AND INTERACTION WITH PIB2.
RX   PubMed=34535752; DOI=10.1038/s42003-021-02625-w;
RA   Tanigawa M., Yamamoto K., Nagatoishi S., Nagata K., Noshiro D., Noda N.N.,
RA   Tsumoto K., Maeda T.;
RT   "A glutamine sensor that directly activates TORC1.";
RL   Commun. Biol. 4:1093-1093(2021).
RN   [28]
RP   FUNCTION.
RX   PubMed=36691768; DOI=10.15252/embj.2022112344;
RA   Shetty S., Hofstetter J., Battaglioni S., Ritz D., Hall M.N.;
RT   "TORC1 phosphorylates and inhibits the ribosome preservation factor Stm1 to
RT   activate dormant ribosomes.";
RL   EMBO J. 42:e112344-e112344(2023).
RN   [29]
RP   STRUCTURE BY NMR OF 2438-2470.
RX   PubMed=15772072; DOI=10.1074/jbc.m501116200;
RA   Dames S.A., Mulet J.M., Rathgeb-Szabo K., Hall M.N., Grzesiek S.;
RT   "The solution structure of the FATC domain of the protein kinase target of
RT   rapamycin suggests a role for redox-dependent structural and cellular
RT   stability.";
RL   J. Biol. Chem. 280:20558-20564(2005).
CC   -!- FUNCTION: Phosphatidylinositol 3-kinase homolog, component of TORC1,
CC       which regulates multiple cellular processes to control cell growth in
CC       response to environmental signals. Nutrient limitation and
CC       environmental stress signals cause inactivation of TORC1. Active TORC1
CC       positively controls ribosome biogenesis via control of rRNA, ribosomal
CC       protein and tRNA gene expression, and rRNA processing. TORC1 positively
CC       controls protein biosynthesis by regulation of mRNA stability,
CC       translation initiation factor activity, and high-affinity amino acid
CC       permeases that serve to provide amino acids for use by the translation
CC       machinery. TORC1 also promotes growth by sequestering a number of
CC       nutrient and general stress-responsive transcription factors in the
CC       cytoplasm. TORC1 negatively controls macroautophagy, a process to
CC       recycle surplus cytoplasmic mass under nutrient starvation conditions.
CC       TORC1 controls many of these processes via TIP41-TAP42-mediated
CC       inhibition of the type 2A-related phosphatases PP2A and SIT4
CC       (PubMed:10198052, PubMed:10329624, PubMed:10604478, PubMed:10995454,
CC       PubMed:11741537, PubMed:15620355, PubMed:28993463, PubMed:7606777,
CC       PubMed:8741837, PubMed:9539725, PubMed:9843498). In nutrient-rich
CC       conditions, responsible for the phosphorylation of AGC S6 kinase (S6K)
CC       YPK3, activating YPK3 kinase activity and promoting phosphorylation of
CC       ribosomal protein S6 (PubMed:25767889). Phosphorylates kinase SCH9 at 6
CC       amino acids in the C-terminus, activating SCH9 kinase activity to
CC       properly regulate ribosome biogenesis, translation initiation, and
CC       entry into stationary phase (PubMed:17560372). Activates dormant
CC       ribosomes by mediating phosphorylation of STM1, leading to STM1
CC       inactivation and reactivation of translation (PubMed:36691768).
CC       {ECO:0000269|PubMed:10198052, ECO:0000269|PubMed:10329624,
CC       ECO:0000269|PubMed:10604478, ECO:0000269|PubMed:10995454,
CC       ECO:0000269|PubMed:11741537, ECO:0000269|PubMed:15620355,
CC       ECO:0000269|PubMed:17560372, ECO:0000269|PubMed:25767889,
CC       ECO:0000269|PubMed:28993463, ECO:0000269|PubMed:36691768,
CC       ECO:0000269|PubMed:7606777, ECO:0000269|PubMed:8741837,
CC       ECO:0000269|PubMed:9539725, ECO:0000269|PubMed:9843498}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP +
CC         H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:10436010};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] +
CC         ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA-
CC         COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:10436010, ECO:0000305|PubMed:34535752};
CC   -!- ACTIVITY REGULATION: Activated by the glutamine sensor PIB2 in
CC       nutrient-rich conditions. {ECO:0000269|PubMed:28483912,
CC       ECO:0000269|PubMed:28993463, ECO:0000269|PubMed:29698392,
CC       ECO:0000269|PubMed:34535752}.
CC   -!- SUBUNIT: The target of rapamycin complex 1 (TORC1) is composed of at
CC       least KOG1, LST8, TCO89 and either TOR1 (TORC1-A) or TOR2 (TORC1-B)
CC       (PubMed:12408816, PubMed:12631735). Interacts with PIB2; following
CC       activation of PIB2 by glutamine or cysteine (PubMed:28483912,
CC       PubMed:29698392, PubMed:34535752). TORC1 binds to and is inhibited by
CC       FKBP-rapamycin (PubMed:12408816, PubMed:7606777).
CC       {ECO:0000269|PubMed:12408816, ECO:0000269|PubMed:12631735,
CC       ECO:0000269|PubMed:28483912, ECO:0000269|PubMed:29698392,
CC       ECO:0000269|PubMed:34535752, ECO:0000269|PubMed:7606777}.
CC   -!- INTERACTION:
CC       P35169; P53233: FMP48; NbExp=3; IntAct=EBI-19374, EBI-9664;
CC       P35169; P20081: FPR1; NbExp=4; IntAct=EBI-19374, EBI-6961;
CC       P35169; P38873: KOG1; NbExp=7; IntAct=EBI-19374, EBI-24864;
CC       P35169; P38691: KSP1; NbExp=2; IntAct=EBI-19374, EBI-9937;
CC       P35169; P41318: LST8; NbExp=5; IntAct=EBI-19374, EBI-28598;
CC       P35169; P34072: MKS1; NbExp=3; IntAct=EBI-19374, EBI-10978;
CC       P35169; P36003: NNK1; NbExp=3; IntAct=EBI-19374, EBI-9796;
CC       P35169; P22211: NPR1; NbExp=2; IntAct=EBI-19374, EBI-12207;
CC       P35169; Q03656: SKY1; NbExp=2; IntAct=EBI-19374, EBI-9800;
CC       P35169; Q08921: TCO89; NbExp=4; IntAct=EBI-19374, EBI-37395;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10973982,
CC       ECO:0000269|PubMed:12631735}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:10973982, ECO:0000269|PubMed:12631735}; Cytoplasmic
CC       side {ECO:0000269|PubMed:10973982, ECO:0000269|PubMed:12631735}.
CC       Vacuole membrane {ECO:0000269|PubMed:12631735,
CC       ECO:0000269|PubMed:28483912, ECO:0000269|PubMed:28993463,
CC       ECO:0000269|PubMed:29698392, ECO:0000269|PubMed:32801125}; Peripheral
CC       membrane protein {ECO:0000269|PubMed:12631735}; Cytoplasmic side
CC       {ECO:0000269|PubMed:12631735}. Note=Also localizes to membranous
CC       structures both proximal to, yet distinct from, the plasma membrane as
CC       well as within the cell interior, probably endosomal or Golgi membranes
CC       (PubMed:10973982). Localization to the vacuolar membrane is dependent
CC       upon PIB2 and GTR1 (PubMed:28993463, PubMed:29698392).
CC       {ECO:0000269|PubMed:10973982, ECO:0000269|PubMed:28993463,
CC       ECO:0000269|PubMed:29698392}.
CC   -!- DISRUPTION PHENOTYPE: Increases cellular levels of glutamine and
CC       alanine during high hydrostatic pressure (mechanical stress)
CC       (PubMed:32801125). Sensitive to high hydrostatic pressure (mechanical
CC       stress) (PubMed:32801125). {ECO:0000269|PubMed:32801125}.
CC   -!- MISCELLANEOUS: It may act on another substrate or phosphorylate a
CC       different position in the phosphatidylinositol ring.
CC   -!- MISCELLANEOUS: Present with 589 molecules/cell in log phase SD medium.
CC       {ECO:0000269|PubMed:14562106}.
CC   -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. {ECO:0000305}.
CC   -!- CAUTION: It is uncertain whether Met-1 is the initiator. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L19540; AAB66881.1; -; Genomic_DNA.
DR   EMBL; X74857; CAA52849.1; -; Genomic_DNA.
DR   EMBL; Z49566; CAA89594.1; -; Genomic_DNA.
DR   EMBL; L47993; AAB39292.1; -; Genomic_DNA.
DR   EMBL; BK006943; DAA08853.1; -; Genomic_DNA.
DR   PIR; S57085; S57085.
DR   RefSeq; NP_012600.1; NM_001181724.1.
DR   PDB; 1W1N; NMR; -; A=2438-2470.
DR   PDB; 2KIO; NMR; -; A=2438-2470.
DR   PDB; 2KIT; NMR; -; A=2438-2470.
DR   PDBsum; 1W1N; -.
DR   PDBsum; 2KIO; -.
DR   PDBsum; 2KIT; -.
DR   AlphaFoldDB; P35169; -.
DR   BMRB; P35169; -.
DR   PCDDB; P35169; -.
DR   SMR; P35169; -.
DR   BioGRID; 33823; 505.
DR   ComplexPortal; CPX-1715; TORC1 serine/threonine-protein kinase complex, TOR1 variant.
DR   DIP; DIP-917N; -.
DR   FunCoup; P35169; 1239.
DR   IntAct; P35169; 39.
DR   MINT; P35169; -.
DR   STRING; 4932.YJR066W; -.
DR   GlyGen; P35169; 1 site.
DR   iPTMnet; P35169; -.
DR   PaxDb; 4932-YJR066W; -.
DR   PeptideAtlas; P35169; -.
DR   EnsemblFungi; YJR066W_mRNA; YJR066W; YJR066W.
DR   GeneID; 853529; -.
DR   KEGG; sce:YJR066W; -.
DR   AGR; SGD:S000003827; -.
DR   SGD; S000003827; TOR1.
DR   VEuPathDB; FungiDB:YJR066W; -.
DR   eggNOG; KOG0891; Eukaryota.
DR   GeneTree; ENSGT00940000174195; -.
DR   HOGENOM; CLU_000178_7_1_1; -.
DR   InParanoid; P35169; -.
DR   OMA; MWLRFVS; -.
DR   OrthoDB; 381190at2759; -.
DR   BioCyc; YEAST:G3O-31699-MONOMER; -.
DR   BRENDA; 2.7.1.137; 984.
DR   BioGRID-ORCS; 853529; 2 hits in 13 CRISPR screens.
DR   EvolutionaryTrace; P35169; -.
DR   PRO; PR:P35169; -.
DR   Proteomes; UP000002311; Chromosome X.
DR   RNAct; P35169; protein.
DR   GO; GO:0005737; C:cytoplasm; IDA:SGD.
DR   GO; GO:0010008; C:endosome membrane; IDA:SGD.
DR   GO; GO:0000329; C:fungal-type vacuole membrane; IDA:SGD.
DR   GO; GO:0000139; C:Golgi membrane; IDA:SGD.
DR   GO; GO:0005634; C:nucleus; IDA:SGD.
DR   GO; GO:0005886; C:plasma membrane; IDA:SGD.
DR   GO; GO:0038201; C:TOR complex; IBA:GO_Central.
DR   GO; GO:0031931; C:TORC1 complex; IPI:SGD.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; IMP:SGD.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0044877; F:protein-containing complex binding; IEA:InterPro.
DR   GO; GO:0034605; P:cellular response to heat; IGI:SGD.
DR   GO; GO:0006995; P:cellular response to nitrogen starvation; IGI:SGD.
DR   GO; GO:0034599; P:cellular response to oxidative stress; IGI:SGD.
DR   GO; GO:0006974; P:DNA damage response; IMP:SGD.
DR   GO; GO:0031505; P:fungal-type cell wall organization; IMP:SGD.
DR   GO; GO:0051321; P:meiotic cell cycle; IMP:SGD.
DR   GO; GO:0031930; P:mitochondria-nucleus signaling pathway; IMP:SGD.
DR   GO; GO:0010507; P:negative regulation of autophagy; IGI:SGD.
DR   GO; GO:0016242; P:negative regulation of macroautophagy; IBA:GO_Central.
DR   GO; GO:0042790; P:nucleolar large rRNA transcription by RNA polymerase I; IMP:SGD.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:CACAO.
DR   GO; GO:0051726; P:regulation of cell cycle; IMP:SGD.
DR   GO; GO:0001558; P:regulation of cell growth; NAS:ComplexPortal.
DR   GO; GO:1905356; P:regulation of snRNA pseudouridine synthesis; IGI:SGD.
DR   GO; GO:0090153; P:regulation of sphingolipid biosynthetic process; IMP:SGD.
DR   GO; GO:0034976; P:response to endoplasmic reticulum stress; IMP:SGD.
DR   GO; GO:0007584; P:response to nutrient; NAS:ComplexPortal.
DR   GO; GO:0042254; P:ribosome biogenesis; IMP:SGD.
DR   GO; GO:0031929; P:TOR signaling; IMP:SGD.
DR   GO; GO:0038202; P:TORC1 signaling; IBA:GO_Central.
DR   GO; GO:0006413; P:translational initiation; IMP:SGD.
DR   CDD; cd05169; PIKKc_TOR; 1.
DR   FunFam; 1.10.1070.11:FF:000020; Serine/threonine-protein kinase TOR; 1.
DR   FunFam; 1.20.120.150:FF:000001; Serine/threonine-protein kinase TOR; 1.
DR   FunFam; 1.25.10.10:FF:000371; Serine/threonine-protein kinase TOR; 1.
DR   FunFam; 1.25.10.10:FF:000601; Serine/threonine-protein kinase TOR; 1.
DR   FunFam; 1.25.10.10:FF:000786; Serine/threonine-protein kinase TOR; 1.
DR   FunFam; 3.30.1010.10:FF:000006; Serine/threonine-protein kinase TOR; 1.
DR   Gene3D; 1.20.120.150; FKBP12-rapamycin binding domain; 1.
DR   Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 4.
DR   Gene3D; 1.10.1070.11; Phosphatidylinositol 3-/4-kinase, catalytic domain; 1.
DR   IDEAL; IID50246; -.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR050517; DDR_Repair_Kinase.
DR   InterPro; IPR003152; FATC_dom.
DR   InterPro; IPR009076; FRB_dom.
DR   InterPro; IPR036738; FRB_sf.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR024585; mTOR_dom.
DR   InterPro; IPR000403; PI3/4_kinase_cat_dom.
DR   InterPro; IPR036940; PI3/4_kinase_cat_sf.
DR   InterPro; IPR018936; PI3/4_kinase_CS.
DR   InterPro; IPR003151; PIK-rel_kinase_FAT.
DR   InterPro; IPR014009; PIK_FAT.
DR   InterPro; IPR026683; TOR_cat.
DR   PANTHER; PTHR11139; ATAXIA TELANGIECTASIA MUTATED ATM -RELATED; 1.
DR   PANTHER; PTHR11139:SF9; SERINE_THREONINE-PROTEIN KINASE MTOR; 1.
DR   Pfam; PF02259; FAT; 1.
DR   Pfam; PF02260; FATC; 1.
DR   Pfam; PF08771; FRB_dom; 1.
DR   Pfam; PF23593; HEAT_ATR; 1.
DR   Pfam; PF11865; mTOR_dom; 1.
DR   Pfam; PF00454; PI3_PI4_kinase; 1.
DR   SMART; SM01346; DUF3385; 1.
DR   SMART; SM01343; FATC; 1.
DR   SMART; SM00146; PI3Kc; 1.
DR   SMART; SM01345; Rapamycin_bind; 1.
DR   SUPFAM; SSF48371; ARM repeat; 2.
DR   SUPFAM; SSF47212; FKBP12-rapamycin-binding domain of FKBP-rapamycin-associated protein (FRAP); 1.
DR   SUPFAM; SSF56112; Protein kinase-like (PK-like); 1.
DR   PROSITE; PS51189; FAT; 1.
DR   PROSITE; PS51190; FATC; 1.
DR   PROSITE; PS00915; PI3_4_KINASE_1; 1.
DR   PROSITE; PS00916; PI3_4_KINASE_2; 1.
DR   PROSITE; PS50290; PI3_4_KINASE_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell cycle; Cell membrane; Kinase; Membrane;
KW   Nucleotide-binding; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Transferase; Vacuole.
FT   CHAIN           1..2470
FT                   /note="Serine/threonine-protein kinase TOR1"
FT                   /id="PRO_0000088813"
FT   REPEAT          114..151
FT                   /note="HEAT 1"
FT                   /evidence="ECO:0000255"
FT   REPEAT          248..286
FT                   /note="HEAT 2"
FT                   /evidence="ECO:0000255"
FT   REPEAT          627..664
FT                   /note="HEAT 3"
FT                   /evidence="ECO:0000255"
FT   REPEAT          663..701
FT                   /note="HEAT 4"
FT                   /evidence="ECO:0000255"
FT   REPEAT          746..784
FT                   /note="HEAT 5"
FT                   /evidence="ECO:0000255"
FT   REPEAT          787..826
FT                   /note="HEAT 6"
FT                   /evidence="ECO:0000255"
FT   REPEAT          829..870
FT                   /note="HEAT 7"
FT                   /evidence="ECO:0000255"
FT   REPEAT          907..946
FT                   /note="HEAT 8"
FT                   /evidence="ECO:0000255"
FT   REPEAT          949..987
FT                   /note="HEAT 9"
FT                   /evidence="ECO:0000255"
FT   REPEAT          1108..1147
FT                   /note="HEAT 10"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          1331..1919
FT                   /note="FAT"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00534"
FT   REPEAT          1869..1907
FT                   /note="HEAT 11"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          2093..2408
FT                   /note="PI3K/PI4K catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   DOMAIN          2438..2470
FT                   /note="FATC"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00535"
FT   REGION          1775..2157
FT                   /note="Interaction with FKBP-rapamycin"
FT                   /evidence="ECO:0000269|PubMed:7606777"
FT   REGION          2099..2105
FT                   /note="G-loop"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   REGION          2272..2280
FT                   /note="Catalytic loop"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   REGION          2292..2317
FT                   /note="Activation loop"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   MUTAGEN         1972
FT                   /note="S->A: No effect."
FT                   /evidence="ECO:0000269|PubMed:7606777,
FT                   ECO:0000269|PubMed:8413204"
FT   MUTAGEN         1972
FT                   /note="S->E,I: Confers resistance to rapamycin. Abolishes
FT                   interaction with FKBP-rapamycin."
FT                   /evidence="ECO:0000269|PubMed:7606777,
FT                   ECO:0000269|PubMed:8413204"
FT   MUTAGEN         1972
FT                   /note="S->N: In DRR1-27; confers resistance to rapamycin."
FT                   /evidence="ECO:0000269|PubMed:7606777,
FT                   ECO:0000269|PubMed:8413204"
FT   MUTAGEN         1972
FT                   /note="S->R: In DRR1-1; confers resistance to rapamycin.
FT                   Abolishes interaction with FKBP-rapamycin."
FT                   /evidence="ECO:0000269|PubMed:7606777,
FT                   ECO:0000269|PubMed:8413204"
FT   MUTAGEN         2176
FT                   /note="W->R: Sensitive to high hydrostatic pressure
FT                   (mechanical stress)."
FT                   /evidence="ECO:0000269|PubMed:32801125"
FT   MUTAGEN         2275
FT                   /note="D->A: Abolishes protein kinase activity."
FT                   /evidence="ECO:0000269|PubMed:10436010"
FT   MUTAGEN         2276
FT                   /note="R->P: Abolishes rapamycin-resistance of mutants
FT                   E-1972; I-1972 and R-1972."
FT                   /evidence="ECO:0000269|PubMed:7606777"
FT   MUTAGEN         2294
FT                   /note="D->E: Abolishes rapamycin-resistance of mutants
FT                   E-1972; I-1972 and R-1972."
FT                   /evidence="ECO:0000269|PubMed:7606777"
FT   CONFLICT        58
FT                   /note="D -> G (in Ref. 1; AAB66881)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        115
FT                   /note="V -> I (in Ref. 1; AAB66881)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        133
FT                   /note="S -> N (in Ref. 1; AAB66881)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        231
FT                   /note="A -> R (in Ref. 2; CAA52849)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        396
FT                   /note="N -> K (in Ref. 1; AAB66881 and 2; CAA52849)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        547
FT                   /note="N -> S (in Ref. 1; AAB66881 and 2; CAA52849)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        675
FT                   /note="T -> I (in Ref. 2; CAA52849)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1292
FT                   /note="G -> E (in Ref. 2; CAA52849)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1436
FT                   /note="G -> A (in Ref. 2; CAA52849)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1468
FT                   /note="A -> R (in Ref. 1; AAB66881 and 2; CAA52849)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1469..1471
FT                   /note="WGL -> GGS (in Ref. 2; CAA52849)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1478..1479
FT                   /note="EQ -> DE (in Ref. 2; CAA52849)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1590
FT                   /note="V -> I (in Ref. 2; CAA52849)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1632..1642
FT                   /note="NDPSLPNTFKA -> TILVYQIRSKP (in Ref. 2; CAA52849)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1640
FT                   /note="F -> V (in Ref. 1; AAB66881)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1844
FT                   /note="L -> S (in Ref. 2; CAA52849)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2202
FT                   /note="H -> Q (in Ref. 1; AAB66881)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2414
FT                   /note="K -> R (in Ref. 1; AAB66881 and 2; CAA52849)"
FT                   /evidence="ECO:0000305"
FT   HELIX           2444..2460
FT                   /evidence="ECO:0007829|PDB:1W1N"
SQ   SEQUENCE   2470 AA;  281140 MW;  ACB1781B9963BB1E CRC64;
     MEPHEEQIWK SKLLKAANND MDMDRNVPLA PNLNVNMNMK MNASRNGDEF GLTSSRFDGV
     VIGSNGDVNF KPILEKIFRE LTSDYKEERK LASISLFDLL VSLEHELSIE EFQAVSNDIN
     NKILELVHTK KTSTRVGAVL SIDTLISFYA YTERLPNETS RLAGYLRGLI PSNDVEVMRL
     AAKTLGKLAV PGGTYTSDFV EFEIKSCLEW LTASTEKNSF SSSKPDHAKH AALLIITALA
     ENCPYLLYQY LNSILDNIWR ALRDPHLVIR IDASITLAKC LSTLRNRDPQ LTSQWVQRLA
     TSCEYGFQVN TLECIHASLL VYKEILFLKD PFLNQVFDQM CLNCIAYENH KAKMIREKIY
     QIVPLLASFN PQLFAGKYLH QIMDNYLEIL TNAPANKIPH LKDDKPQILI SIGDIAYEVG
     PDIAPYVKQI LDYIEHDLQT KFKFRKKFEN EIFYCIGRLA VPLGPVLGKL LNRNILDLMF
     KCPLSDYMQE TFQILTERIP SLGPKINDEL LNLVCSTLSG TPFIQPGSPM EIPSFSRERA
     REWRNKNILQ KTGESNDDNN DIKIIIQAFR MLKNIKSRFS LVEFVRIVAL SYIEHTDPRV
     RKLAALTSCE IYVKDNICKQ TSLHSLNTVS EVLSKLLAIT IADPLQDIRL EVLKNLNPCF
     DPQLAQPDNL RLLFTALHDE SFNIQSVAME LVGRLSSVNP AYVIPSIRKI LLELLTKLKF
     STSSREKEET ASLLCTLIRS SKDVAKPYIE PLLNVLLPKF QDTSSTVAST ALRTIGELSV
     VGGEDMKIYL KDLFPLIIKT FQDQSNSFKR EAALKALGQL AASSGYVIDP LLDYPELLGI
     LVNILKTENS QNIRRQTVTL IGILGAIDPY RQKEREVTST TDISTEQNAP PIDIALLMQG
     MSPSNDEYYT TVVIHCLLKI LKDPSLSSYH TAVIQAIMHI FQTLGLKCVS FLDQIIPTIL
     DVMRTCSQSL LEFYFQQLCS LIIIVRQHIR PHVDSIFQAI KDFSSVAKLQ ITLVSVIEAI
     SKALEGEFKR LVPLTLTLFL VILENDKSSD KVLSRRVLRL LESFGPNLEG YSHLITPKIV
     QMAEFTSGNL QRSAIITIGK LAKDVDLFEM SSRIVHSLLR VLSSTTSDEL SKVIMNTLSL
     LLIQMGTSFA IFIPVINEVL MKKHIQHTIY DDLTNRILNN DVLPTKILEA NTTDYKPAEQ
     MEAADAGVAK LPINQSVLKS AWNSSQQRTK EDWQEWSKRL SIQLLKESPS HALRACSNLA
     SMYYPLAKEL FNTAFACVWT ELYSQYQEDL IGSLCIALSS PLNPPEIHQT LLNLVEFMEH
     DDKALPIPTQ SLGEYAERCH AYAKALHYKE IKFIKEPENS TIESLISINN QLNQTDAAIG
     ILKHAQQHHS LQLKETWFEK LERWEDALHA YNEREKAGDT SVSVTLGKMR SLHALGEWEQ
     LSQLAARKWK VSKLQTKKLI APLAAGAAWG LGEWDMLEQY ISVMKPKSPD KEFFDAILYL
     HKNDYDNASK HILNARDLLV TEISALINES YNRAYSVIVR TQIITEFEEI IKYKQLPPNS
     EKKLHYQNLW TKRLLGCQKN VDLWQRVLRV RSLVIKPKQD LQIWIKFANL CRKSGRMRLA
     NKALNMLLEG GNDPSLPNTF KAPPPVVYAQ LKYIWATGAY KEALNHLIGF TSRLAHDLGL
     DPNNMIAQSV KLSSASTAPY VEEYTKLLAR CFLKQGEWRI ATQPNWRNTN PDAILGSYLL
     ATHFDKNWYK AWHNWALANF EVISMVQEET KLNGGKNDDD DDTAVNNDNV RIDGSILGSG
     SLTINGNRYP LELIQRHVVP AIKGFFHSIS LLETSCLQDT LRLLTLLFNF GGIKEVSQAM
     YEGFNLMKIE NWLEVLPQLI SRIHQPDPTV SNSLLSLLSD LGKAHPQALV YPLTVAIKSE
     SVSRQKAALS IIEKIRIHSP VLVNQAELVS HELIRVAVLW HELWYEGLED ASRQFFVEHN
     IEKMFSTLEP LHKHLGNEPQ TLSEVSFQKS FGRDLNDAYE WLNNYKKSKD INNLNQAWDI
     YYNVFRKITR QIPQLQTLDL QHVSPQLLAT HDLELAVPGT YFPGKPTIRI AKFEPLFSVI
     SSKQRPRKFS IKGSDGKDYK YVLKGHEDIR QDSLVMQLFG LVNTLLKNDS ECFKRHLDIQ
     QYPAIPLSPK SGLLGWVPNS DTFHVLIREH RDAKKIPLNI EHWVMLQMAP DYENLTLLQK
     IEVFTYALDN TKGQDLYKIL WLKSRSSETW LERRTTYTRS LAVMSMTGYI LGLGDRHPSN
     LMLDRITGKV IHIDFGDCFE AAILREKYPE KVPFRLTRML TYAMEVSGIE GSFRITCENV
     MRVLRDNKES LMAILEAFAL DPLIHWGFDL PPQKLTEQTG IPLPLINPSE LLRKGAITVE
     EAANMEAEQQ NETKNARAML VLRRITDKLT GNDIKRFNEL DVPEQVDKLI QQATSIERLC
     QHYIGWCPFW
//
